Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
The Nassau Guardian22 小时
Chronic kidney disease projected to be 5th leading cause of death in five years
With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...